Citations

Showing 10 of 108152 citations.

Novel Insights into Mechanisms of Intestinal Phosphate Absorption in Patients with Chronic Kidney Disease
Kritmetapak, Kittrawee , Kumar, Rajiv , Kumar, Rajiv

Mayo Clinic

Journal of the American Society of Nephrology | July 30, 2021 | Volume: 32 | Issue: 8 | Pages: 1830-1832

10.1681/asn.2021050610 | PMID 34330767 Get It

Zonation in NASH – A key paradigm for understanding pathophysiology and clinical outcomes
Steinman, Jonathan B. , Salomao, Marcela A, Salomao, Marcela , Pajvani, Utpal B.

Mayo Clinic

Liver International | July 30, 2021 | Volume: 41 | Issue: 11 | Pages: 2534-2546

10.1111/liv.15025 | PMID 34328687 Get It

AbstractNon‐alcoholic fatty liver disease (NAFLD) exists as a spectrum ranging from simple steatosis to histologically defined hepatocyte injury and inflammatory changes that define steatohepatitis (NASH), and increase risk for fibrosis. Although zonal differences in NASH have not been systematically studied, periportal involvement has been associated with worse metabolic outcomes and more hepatic fibrosis as compared to pericentral disease. These data suggest that hepatic zonation of disease may influence the diversity of clinical presentations. Similarly, several randomized clinical trials suggest a differential response based on zonation of disease, with preferential effects on periportal (cysteamine) or pericentral disease (obeticholic acid, pioglitazone). Intriguingly, morphogenic pathways known to affect zonal development and maintenance – WNT/β‐Catenin, Hedgehog, HIPPO/Yap/TAZ and Notch – have been implicated in NASH pathogenesis, and nuclear hormone receptors downstream of potential NASH therapeutics show zonal preferences. In this review, we summarize these data and propose that patient‐specific activation of these pathways may explain the variability in clinical presentation, and the zone‐specific response observed in clinical trials.
Ipsilateral and Simultaneous Comparison of Responses from Acceleromyography- and Electromyography-based Neuromuscular Monitors
Nemes, Réka, Nagy, György M., Hampton, David R., Gray, Martyn, Brull, Sorin J. , Brull, Sorin J , Lengyel, Szabolcs, Nagy, György, Renew, J. Ross , TASSONYI, Edömer , Fülesdi, Béla

Mayo Clinic

Anesthesiology | July 30, 2021 | Volume: 135 | Issue: 4 | Pages: 597-611

10.1097/aln.0000000000003896 | PMID 34329371 Get It

Background The paucity of easy-to-use, reliable objective neuromuscular monitors is an obstacle to universal adoption of routine neuromuscular monitoring. Electromyography (EMG) has been proposed as the optimal neuromuscular monitoring technology since it addresses several acceleromyography limitations. This clinical study compared simultaneous neuromuscular responses recorded from induction of neuromuscular block until recovery using the acceleromyography-based TOF-Watch SX and EMG-based TetraGraph. Methods Fifty consenting patients participated. The acceleromyography and EMG devices analyzed simultaneous contractions (acceleromyography) and muscle action potentials (EMG) from the adductor pollicis muscle by synchronization via fiber optic cable link. Bland–Altman analysis described the agreement between devices during distinct phases of neuromuscular block. The primary endpoint was agreement of acceleromyography- and EMG-derived normalized train-of-four ratios greater than or equal to 80%. Secondary endpoints were agreement in the recovery train-of-four ratio range less than 80% and agreement of baseline train-of-four ratios between the devices. Results Acceleromyography showed normalized train-of-four ratio greater than or equal to 80% earlier than EMG. When acceleromyography showed train-of-four ratio greater than or equal to 80% (n = 2,929), the bias was 1.3 toward acceleromyography (limits of agreement, –14.0 to 16.6). When EMG showed train-of-four ratio greater than or equal to 80% (n = 2,284), the bias was –0.5 toward EMG (–14.7 to 13.6). In the acceleromyography range train-of-four ratio less than 80% (n = 2,802), the bias was 2.1 (–16.1 to 20.2), and in the EMG range train-of-four ratio less than 80% (n = 3,447), it was 2.6 (–14.4 to 19.6). Baseline train-of-four ratios were higher and more variable with acceleromyography than with EMG. Conclusions Bias was lower than in previous studies. Limits of agreement were wider than expected because acceleromyography readings varied more than EMG both at baseline and during recovery. The EMG-based monitor had higher precision and greater repeatability than acceleromyography. This difference between monitors was even greater when EMG data were compared to raw (nonnormalized) acceleromyography measurements. The EMG monitor is a better indicator of adequate recovery from neuromuscular block and readiness for safe tracheal extubation than the acceleromyography monitor. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
Safety and efficacy of endoscopic cyanoacrylate injection in the management of gastric varices: A systematic review and meta‐analysis
Chirapongsathorn, Sakkarin , Manatsathit, Wuttiporn , Suksamai, Anuchit , Farrell, Ann

Mayo Clinic

JGH Open | July 30, 2021 | Volume: 5 | Issue: 9 | Pages: 1047-1055

10.1002/jgh3.12629 | PMID 34584974 Get It

AbstractBackground and AimBleeding from gastric varices is a catastrophic event and poses difficulty in management. The efficacy and safety of cyanoacrylate injection remain unclear. We performed a systematic review and meta‐analysis to evaluate the effect of endoscopic cyanoacrylate injection in the management of gastric varices.MethodsWe conducted a comprehensive search of MEDLINE, Embase, Web of Science, Scopus databases, and Cochrane Database of Systematic Reviews through November 2020 and manually reviewed the literature. Trial‐specific risk ratios (RRs) were estimated and pooled using random‐effect model meta‐analysis.ResultsWe included seven randomized controlled trials (six for secondary prophylaxis and one for primary prophylaxis) at low risk of bias in which 126 deaths were reported among 583 patients with gastric varices. All studies reported the use of N‐butyl‐2‐cyanoacrylate glue. Cyanoacrylate use was associated with significantly lower all‐cause mortality (RR, 0.59; 95% confidence interval [CI], 0.36–0.98; I2 = 41%) and rebleeding rate after hemostasis (RR, 0.49; 95% CI, 0.35–0.68, I2 = 0%) compared with any other treatment approach not involving cyanoacrylate. When cyanoacrylate was compared with each individual treatment approach (propranolol only, band ligation, sclerotherapy with alcohol or ethanolamine), data comprised sparse limited comparative conclusions. The use of cyanoacrylate injection was not associated with an increase in serious adverse events. The quality of evidence is moderate, graded down due to the small number of events and wide CIs.ConclusionThe use of endoscopic cyanoacrylate injection therapy for gastric varices may be associated with lower all‐cause mortality and better hemostasis compared with other therapies.
Fatal recurrent disseminated Lomentospora prolificans infection during autologous hematopoietic stem cell transplantation: A case report and review, and discussion on the importance of prolonged neutropenia
Gow‐Lee, Vanessa J. , Moyers, Justin T. , Rogstad, Daniel K. , Gow-Lee, Vanessa

Mayo Clinic

Transplant Infectious Disease | July 30, 2021 | Volume: 23 | Issue: 6 | Pages: No page available

10.1111/tid.13701 | PMID 34328649 Get It

AbstractInfections with Scedosporium and Lomentospora species, in particular Lomentospora (previously Scedosporium) prolificans, are nearly universally fatal and rapidly‐progressive in the transplant population. We report a case of a patient with diffuse large B‐cell lymphoma undergoing myelosuppressive chemotherapy who developed disseminated L. prolificans infection which afterward persisted in his knee joint. The infection was treated with early empiric triple antifungal therapy tailored to synergy studies, growth factors to quickly resolve neutropenia, and aggressive debridement (where possible) of infection sites, including amputation. He achieved an 11‐month remission until undergoing autologous hematopoietic stem cell transplantation with deep myelosuppression, wherein recrudescent L. prolificans infection occurred, causing death. We highlight the importance of early treatment, synergy studies, and especially recovery of neutropenia in treating this devastating condition.
Treatment of CSF1R‐Related Leukoencephalopathy: Breaking New Ground
Tipton, Philip W. , Kenney‐Jung, Daniel , Rush, Beth , Middlebrooks, Erik H. , Nascene, David , Singh, Balvindar , Holtan, Shernan G. , Ayala, Ernesto , Broderick, Daniel F. , Middlebrooks, Erik H , Tipton, Philip W , Holtan, Shernan , Lund, Troy C. , Wszołek, Zbigniew K.

Mayo Clinic

Movement Disorders | July 30, 2021 | Volume: 36 | Issue: 12 | Pages: 2901-2909

10.1002/mds.28734 | PMID 34329526 Get It

AbstractBackgroundColony‐stimulating factor‐1 receptor (CSF1R)‐related leukoencephalopathy is a rapidly progressive neurodegenerative disease for which there is currently no cure. Hematopoietic stem cell transplantation (HSCT) has been proposed as a disease‐modifying treatment.ObjectiveThe objective of this study was to determine the effect of HSCT on disease progression.MethodsWe collected all available clinical data from a cohort of 7 patients with CSF1R‐related leukoencephalopathy who underwent HSCT at our institutions. Clinical data included detailed neurological examination by a board‐certified neurologist, serial cognitive screens, formal neuropsychological evaluations, and serial brain magnetic resonance imaging (MRI).ResultsOur patients had an average disease duration of 27.6 months at the time of transplant, and we have 87 months of total posttransplant follow‐up time (median, 11; range, 2–27). One patient died in the periprocedural period. The remaining patients showed a variable response to treatment, with 6 of 7 patients trending toward stabilization on motor examination, cognitive scores, and/or MRI abnormalities, especially with white matter lesion burden.ConclusionsThis is the largest series of patients with CSF1R‐related leukoencephalopathy receiving HSCT. We conclude that HSCT can stabilize the disease in some patients. Variability in patient responsiveness suggests that measures of disease heterogeneity and severity need to be considered when evaluating a patient's candidacy for transplant. HSCT appears to be the first disease‐modifying therapy for CSF1R‐related leukoencephalopathy. This milestone may serve as a foothold toward better understanding the disease's pathomechanism, thus providing new opportunities for better disease‐specific therapies. © 2021 International Parkinson and Movement Disorder Society
Evaluating safety in hyaluronic acid lip injections
Safran, Tyler , Swift, Arthur, Nikolis, Andreas , Cotofana, Sebastian

Mayo Clinic

Expert Opinion on Drug Safety | July 30, 2021 | Volume: 20 | Issue: 12 | Pages: 1473-1486

10.1080/14740338.2021.1962283 | PMID 34328377 Get It

Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and handled inappropriately
Khan, Nasim A. , Torralba, Karina D. , Aslam, Fawad , Aslam, Fawad

Mayo Clinic

RMD Open | July 30, 2021 | Volume: 7 | Issue: 2 | Pages: e001708

10.1136/rmdopen-2021-001708 | PMID 34330848 Get It

Objectives To analyse the amount, reporting and handling of missing data, approach to intention-to-treat (ITT) principle application and sensitivity analysis utilisation in randomised clinical trials (RCTs) of rheumatoid arthritis (RA). To assess the trend in such reporting 10 years apart (2006 and 2016). Methods Parallel group drug therapy RA RCTs with a clinical primary endpoint. Results 176 studies enrolling a median of 160 (IQR 62–339) patients were eligible. In terms of actual analysis: 81 (46%) RCTs conducted ITT, 42 (23.9%) conducted modified ITT while 53 (30.1%) conducted non-ITT analysis. Only 58 of 97 (59.8%) RCTs reporting an ITT analysis actually performed it. The median (IQR) numbers of participants completing the trial and included in analysis for primary outcome were 86% (74%–91%) and 100% (97.1%–100%), respectively. 53 (32.7%) and 65 (40.1%) RCTs had >20% and 10%–20% missing primary outcome data, respectively. Missing data handling was unreported by 58 of 171 (33.9%) RCTs. When reported, vast majority used simple imputation methods. No significant trend towards improved reporting was seen between 2006 and 2016. Sensitivity analysis numerically improved from 2006 to 2016 (14.7% vs 21.4%). Conclusions There is significant discrepancy in the reported and the actual performed analysis in RA drug therapy RCTs. Nearly one-third of RCTs had >20% missing data. The reporting and methods of missing data handling remain inadequate with high usage of non-preferred simple imputation methods. Sensitivity analysis utilisation was low. No trend towards better missing data reporting and handling was seen.
CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions
Pandey, Veethika , Martinez, Alicia K. Fleming , Bastea, Ligia I. , Doeppler, Heike, Eisenhauer, Jillian, Edenfield, Brandy , Störz, Peter , Fleming-Martinez, Alicia, Bastea, Ligia, Doeppler, Heike R, Le, Tam, Storz, Peter , Bastea, Ligia , Döppler, Heike, Le, Tam

Mayo Clinic

eLife | July 30, 2021 | Volume: 10 | Issue: No issue available | Pages: No page available

10.7554/elife.60646 | PMID 34328416 Get It

The development of pancreatic cancer requires recruitment and activation of different macrophage populations. However, little is known about how macrophages are attracted to the pancreas after injury or an oncogenic event, and how they crosstalk with lesion cells or other cells of the lesion microenvironment. Here, we delineate the importance of CXCL10/CXCR3 signaling during the early phase of murine pancreatic cancer. We show that CXCL10 is produced by pancreatic precancerous lesion cells in response to IFNγ signaling and that inflammatory macrophages are recipients for this chemokine. CXCL10/CXCR3 signaling in macrophages mediates their chemoattraction to the pancreas, enhances their proliferation, and maintains their inflammatory identity. Blocking of CXCL10/CXCR3 signaling in vivo shifts macrophage populations to a tumor-promoting (Ym1 + , Fizz + , Arg1 + ) phenotype, increases fibrosis, and mediates progression of lesions, highlighting the importance of this pathway in PDA development. This is reversed when CXCL10 is overexpressed in PanIN cells.
A paramedian approach for dorsal root ganglion stimulation placement developed to limit lead migration and fracture
Chapman, Kenneth B. , Spiegel, Matthew A., Dickerson, David , Billet, Bart , Patel, Kiran V., Hunter, Corey , Antony, Ajay, Helmond, Noud van , Kallewaard, Jan Willem , Yang, Ajax , van Helmond, Noud , Hagedorn, Jonathan M , Dickerson, David M , Deer, Timothy R. , Hagedorn, Jonathan M.

Mayo Clinic

Pain Practice | July 30, 2021 | Volume: 21 | Issue: 8 | Pages: 991-1000

10.1111/papr.13063 | PMID 34328256 Get It

Abstract Introduction Dorsal root ganglion stimulation (DRG‐S), has demonstrated superiority in the treatment of complex regional pain syndrome and causalgia. Lead migration and fracture impact DRG‐S therapeutic stability. Lead anchoring reduces DRG‐S lead migration without increasing lead fracture. Lead fracture may be related to lead entrapment in the superficial fascial plane. A novel medialized approach for lead placement and anchoring is presented to address these issues. Methods We suggest an alternative technique for implanting percutaneous DRG‐S leads at the T10‐L5 levels. Results A novel medialized ipsilateral technique for lead placement and anchoring for single, bilateral, and adjacent segment placement is presented. The Tuohy needle puncture site is medial to the pedicle and adjacent to the spinous process, two vertebral levels caudad to the target foramen. Trajectory is maintained in the sagittal plane, to access the caudad interlaminar space near the midline. This technique allows for ipsilateral or contralateral lead placement. After epidural access, the introducer sheath is rotated toward the targeted foramen and advanced. The guidewire followed by the lead is passed, and once lead position is confirmed, tension “S” loops are created, followed by anchoring to the deep fascia. Conclusion We describe a new paramedian technique for DRG‐S lead placement. We propose it will decrease DRG‐S complication rates through anchoring to reduce migration and by avoiding the fascial planes thought to be responsible for fracture. Long‐term outcomes applying our proposed techniques are required for determining the true impact, however, early anecdotal results suggest that these new techniques are favorable.